SK146199A3 - Farnesyltransferase inhibiting quinazolinones - Google Patents

Farnesyltransferase inhibiting quinazolinones Download PDF

Info

Publication number: SK146199A3
Authority: SK; Slovakia
Prior art keywords: alkyl; hydrogen; formula; compound; halo
Prior art date: 1997-04-25

Application number

SK1461-99A

Other languages

English (en)

Slovak (sk)

Inventor

Patrick Rene Angibaud

Marc Gaston Venet

Eddy Jean Edgard Freyne

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-25

Filing date

1998-04-17

Publication date

2000-06-12

1998-04-17 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2000-06-12 Publication of SK146199A3 publication Critical patent/SK146199A3/sk

Links

230000002401 inhibitory effect Effects 0.000 title abstract description 5
102000007317 Farnesyltranstransferase Human genes 0.000 title abstract description 3
108010007508 Farnesyltranstransferase Proteins 0.000 title abstract description 3
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title description 9
150000001875 compounds Chemical class 0.000 claims abstract description 112
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 76
239000001257 hydrogen Substances 0.000 claims abstract description 75
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 50
239000002253 acid Substances 0.000 claims abstract description 22
150000002431 hydrogen Chemical class 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 19
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
238000002360 preparation method Methods 0.000 claims abstract description 10
229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 8
239000001301 oxygen Substances 0.000 claims abstract description 8
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052717 sulfur Chemical group 0.000 claims abstract description 4
239000011593 sulfur Chemical group 0.000 claims abstract description 4
125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 4
125000004076 pyridyl group Chemical group 0.000 claims abstract 3
125000000217 alkyl group Chemical group 0.000 claims description 107
125000005843 halogen group Chemical group 0.000 claims description 30
125000003545 alkoxy group Chemical group 0.000 claims description 28
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 25
-1 C _' Chemical group 0.000 claims description 23
238000006243 chemical reaction Methods 0.000 claims description 20
238000000034 method Methods 0.000 claims description 18
239000002585 base Substances 0.000 claims description 12
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
239000013067 intermediate product Substances 0.000 claims description 5
230000009466 transformation Effects 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
150000002576 ketones Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 3
150000003863 ammonium salts Chemical class 0.000 claims description 3
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
239000003513 alkali Substances 0.000 claims 2
239000012458 free base Substances 0.000 claims 2
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
235000018906 Bauhinia malabarica Nutrition 0.000 claims 1
244000300022 Bauhinia malabarica Species 0.000 claims 1
101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 claims 1
125000001425 triazolyl group Chemical group 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 77
239000003814 drug Substances 0.000 abstract description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
125000001475 halogen functional group Chemical group 0.000 abstract 4
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 2
125000004951 trihalomethoxy group Chemical group 0.000 abstract 2
125000004953 trihalomethyl group Chemical group 0.000 abstract 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
239000000543 intermediate Substances 0.000 description 63
239000002904 solvent Substances 0.000 description 47
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
210000004027 cell Anatomy 0.000 description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 24
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 20
239000012044 organic layer Substances 0.000 description 19
239000002244 precipitate Substances 0.000 description 19
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 15
239000000047 product Substances 0.000 description 15
108010037444 diisopropylglutathione ester Proteins 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
239000000460 chlorine Substances 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 13
239000000741 silica gel Substances 0.000 description 13
229910002027 silica gel Inorganic materials 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 12
125000001309 chloro group Chemical group Cl* 0.000 description 12
NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
238000004440 column chromatography Methods 0.000 description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
108010014186 ras Proteins Proteins 0.000 description 10
102000016914 ras Proteins Human genes 0.000 description 10
239000012279 sodium borohydride Substances 0.000 description 10
229910000033 sodium borohydride Inorganic materials 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
108700042226 ras Genes Proteins 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
239000003480 eluent Substances 0.000 description 8
239000012312 sodium hydride Substances 0.000 description 8
229910000104 sodium hydride Inorganic materials 0.000 description 8
238000012360 testing method Methods 0.000 description 8
230000010261 cell growth Effects 0.000 description 7
230000035772 mutation Effects 0.000 description 7
231100000590 oncogenic Toxicity 0.000 description 7
230000002246 oncogenic effect Effects 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
101100386699 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) dcl-1 gene Proteins 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000005457 ice water Substances 0.000 description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000010992 reflux Methods 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000012442 inert solvent Substances 0.000 description 4
229960004592 isopropanol Drugs 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
238000007126 N-alkylation reaction Methods 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
PEQMJVGRHNZPAM-UHFFFAOYSA-N 1,4-dichloro-2-isocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=O)=C1 PEQMJVGRHNZPAM-UHFFFAOYSA-N 0.000 description 2
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
101150040459 RAS gene Proteins 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052799 carbon Chemical group 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000030944 contact inhibition Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000002140 halogenating effect Effects 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000001294 propane Substances 0.000 description 2
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
238000006798 ring closing metathesis reaction Methods 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229960005137 succinic acid Drugs 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
VWVZFHRDLPHBEG-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfanylbenzene Chemical group CSC1=CC=C(CCl)C=C1 VWVZFHRDLPHBEG-UHFFFAOYSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
DHYPBWUEWJLYAZ-UHFFFAOYSA-N 4-(3-chlorophenyl)-1-methylquinazolin-2-one Chemical compound CN1C(N=C(C2=CC=CC=C12)C1=CC(=CC=C1)Cl)=O DHYPBWUEWJLYAZ-UHFFFAOYSA-N 0.000 description 1
KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
210000004128 D cell Anatomy 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
101710113436 GTPase KRas Proteins 0.000 description 1
102100039788 GTPase NRas Human genes 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
239000003098 androgen Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
206010004398 benign neoplasm of skin Diseases 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000006126 farnesylation Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
238000000926 separation method Methods 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
239000002356 single layer Substances 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000004544 spot-on Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
PNQBEPDZQUOCNY-UHFFFAOYSA-N trifluoroacetyl chloride Chemical compound FC(F)(F)C(Cl)=O PNQBEPDZQUOCNY-UHFFFAOYSA-N 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Silver Salt Photography Or Processing Solution Therefor (AREA)
Cosmetics (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

SK1461-99A 1997-04-25 1998-04-17 Farnesyltransferase inhibiting quinazolinones SK146199A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP97201259		1997-04-25
PCT/EP1998/002357 WO1998049157A1 (en)	1997-04-25	1998-04-17	Farnesyltransferase inhibiting quinazolinones

Publications (1)

Publication Number	Publication Date
SK146199A3 true SK146199A3 (en)	2000-06-12

Family

ID=8228267

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1461-99A SK146199A3 (en)	1997-04-25	1998-04-17	Farnesyltransferase inhibiting quinazolinones

Country Status (22)

Country	Link
US (2)	US6177432B1 (no)
EP (1)	EP0977750B1 (no)
JP (1)	JP4308919B2 (no)
KR (1)	KR100520401B1 (no)
CN (1)	CN1094937C (no)
AT (1)	ATE366250T1 (no)
AU (1)	AU738628B2 (no)
BR (1)	BR9809398A (no)
CA (1)	CA2288140C (no)
CZ (1)	CZ296959B6 (no)
DE (1)	DE69838025T2 (no)
ES (1)	ES2289783T3 (no)
HU (1)	HUP0001122A3 (no)
IL (1)	IL130363A (no)
NO (1)	NO317576B1 (no)
NZ (1)	NZ336233A (no)
PL (1)	PL190944B1 (no)
RU (1)	RU2205831C2 (no)
SK (1)	SK146199A3 (no)
TR (1)	TR199902606T2 (no)
WO (1)	WO1998049157A1 (no)
ZA (1)	ZA983504B (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2205831C2 (ru) *	1997-04-25	2003-06-10	Янссен Фармацевтика Н.В.	Хиназолиноны, ингибирующие фарнезилтрансферазу
HRP20000904A2 (en)	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
WO2000034437A2 (en)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
WO2000034239A2 (en)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
ID29241A (id) *	1998-12-23	2001-08-16	Janssen Pharmaceutica Nv	Turunan-turunan kinolin teranelasi-1,2
KR20010077400A (ko) *	2000-02-02	2001-08-17	성재갑	에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제
JP5491681B2 (ja) *	2000-02-04	2014-05-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en)	2000-02-24	2005-01-04	Janssen Pharmaceutica N. V.	Dosing regimen
JP2003525239A (ja) *	2000-02-29	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US20030078281A1 (en) *	2000-02-29	2003-04-24	Rybak Mary Ellen Margaret	Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
WO2001064196A2 (en) *	2000-02-29	2001-09-07	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2001064194A2 (en) *	2000-02-29	2001-09-07	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with camptothecin compounds
JP2003525252A (ja) *	2000-02-29	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
CA2397448A1 (en) *	2000-02-29	2001-09-07	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1261343A2 (en) *	2000-02-29	2002-12-04	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US20030027808A1 (en) *	2000-02-29	2003-02-06	Palmer Peter Albert	Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001244167A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001252147A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations
EP1267871A2 (en) *	2000-02-29	2003-01-02	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
JO2361B1 (en) *	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US7067531B2 (en)	2000-09-25	2006-06-27	Angibaud Patrick Rene	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024682A1 (en) *	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
WO2002024686A2 (en) *	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7173040B2 (en)	2000-09-25	2007-02-06	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
JP4348080B2 (ja) *	2000-11-21	2009-10-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体
DK1339407T3 (da) *	2000-11-28	2006-08-14	Janssen Pharmaceutica Nv	Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
ES2260316T3 (es)	2000-12-27	2006-11-01	Janssen Pharmaceutica N.V.	Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
JP4969016B2 (ja) *	2001-02-15	2012-07-04	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
BRPI0208075B8 (pt) *	2001-03-12	2021-05-25	Janssen Pharmaceutica Nv	processo para a preparação de compostos de imidazol
US20020177575A1 (en) *	2001-05-04	2002-11-28	Ward Wakeland	Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
ATE425978T1 (de) *	2001-12-19	2009-04-15	Janssen Pharmaceutica Nv	Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
FR2837201A1 (fr) *	2002-03-18	2003-09-19	Servier Lab	Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4450628B2 (ja)	2002-03-22	2010-04-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
ATE336496T1 (de)	2002-04-15	2006-09-15	Janssen Pharmaceutica Nv	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20030125268A1 (en) *	2002-08-28	2003-07-03	Rybak Mary Ellen Margaret	Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20050272068A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	UCH-L1 expression and cancer therapy
US20060106060A1 (en) *	2004-03-18	2006-05-18	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies (Lansbury)
US20050272722A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
JP2007529555A (ja) *	2004-03-18	2007-10-25	ザブライハムアンドウイメンズホスピタル，インコーポレイテッド	シヌクレイノパチーを治療する方法
CA2559285A1 (en) *	2004-03-18	2005-09-29	Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
EP1655289A1 (en) *	2004-11-04	2006-05-10	Embl	Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives
HRP20130399T1 (hr)	2004-11-05	2013-06-30	Janssen Pharmaceutica Nv	Terapeutska upotreba inhibitora farenziltransferaze i postupci praä†enja njihove efikasnosti
US20060194821A1 (en) *	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
EP1871347B1 (en)	2005-04-19	2016-08-03	Novartis AG	Pharmaceutical composition
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CA2634598A1 (en)	2005-12-23	2007-07-05	Link Medicine Corporation	Treatment of synucleinopathies
WO2007124319A1 (en)	2006-04-20	2007-11-01	Janssen Pharmaceutica N.V.	Inhibitors of c-fms kinase
PL2021335T3 (pl)	2006-04-20	2011-10-31	Janssen Pharmaceutica Nv	Związki heterocykliczne jako inhibitory kinazy C-FMS
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
CN101600698B (zh)	2006-09-11	2012-01-11	欧加农股份有限公司;药典有限责任公司	喹唑啉酮和异喹啉酮乙酰胺衍生物
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
US7932036B1 (en)	2008-03-12	2011-04-26	Veridex, Llc	Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (en) *	2008-03-12	2009-12-17	Link Medicine Corporation	Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
NZ593090A (en) *	2008-11-13	2013-06-28	Link Medicine Corp	Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US8431576B2 (en)	2009-06-25	2013-04-30	Alkermes Pharma Ireland Limited	Heterocyclic compounds for the treatment of neurological and psychological disorders
ES2705719T3 (es)	2010-07-28	2019-03-26	Janssen Diagnostics Llc	Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
ES2658773T3 (es)	2012-08-07	2018-03-12	Janssen Pharmaceutica N.V.	Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo
CN104870454B (zh)	2012-08-07	2020-03-03	詹森药业有限公司	用于制备杂环酯衍生物的方法
CN103275085B (zh) *	2013-05-30	2015-04-08	温州大学	一种喹唑啉并喹唑啉酮化合物及其合成方法和用途
SMT202100712T1 (it)	2015-08-17	2022-01-10	Kura Oncology Inc	Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
TW201818965A (zh)	2016-11-03	2018-06-01	美商庫拉腫瘤技術股份有限公司	以法呢基轉移酶（ｆａｒｎｅｓｙｌｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
WO2019113269A1 (en)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
EP3761983A1 (en)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
US20220143006A1 (en)	2019-03-15	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2002864C (en) *	1988-11-29	1999-11-16	Eddy J. E. Freyne	(1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
US5430148A (en) *	1992-03-31	1995-07-04	Agouron Pharmaceuticals, Inc.	Antiproliferative quinazolines
WO1994007498A1 (fr) *	1992-10-07	1994-04-14	Sumitomo Pharmaceuticals Company, Limited	Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
TW321649B (no)	1994-11-12	1997-12-01	Zeneca Ltd
RU2205831C2 (ru) *	1997-04-25	2003-06-10	Янссен Фармацевтика Н.В.	Хиназолиноны, ингибирующие фарнезилтрансферазу

1998
- 1998-04-17 RU RU99124815/04A patent/RU2205831C2/ru active
- 1998-04-17 HU HU0001122A patent/HUP0001122A3/hu unknown
- 1998-04-17 ES ES98924161T patent/ES2289783T3/es not_active Expired - Lifetime
- 1998-04-17 AU AU76460/98A patent/AU738628B2/en not_active Expired
- 1998-04-17 IL IL13036398A patent/IL130363A/en not_active IP Right Cessation
- 1998-04-17 CZ CZ0371799A patent/CZ296959B6/cs not_active IP Right Cessation
- 1998-04-17 CA CA002288140A patent/CA2288140C/en not_active Expired - Lifetime
- 1998-04-17 KR KR10-1999-7005507A patent/KR100520401B1/ko not_active Expired - Fee Related
- 1998-04-17 BR BR9809398-3A patent/BR9809398A/pt not_active Application Discontinuation
- 1998-04-17 DE DE69838025T patent/DE69838025T2/de not_active Expired - Lifetime
- 1998-04-17 US US09/403,705 patent/US6177432B1/en not_active Expired - Lifetime
- 1998-04-17 EP EP98924161A patent/EP0977750B1/en not_active Expired - Lifetime
- 1998-04-17 TR TR1999/02606T patent/TR199902606T2/xx unknown
- 1998-04-17 JP JP54656198A patent/JP4308919B2/ja not_active Expired - Lifetime
- 1998-04-17 PL PL336468A patent/PL190944B1/pl unknown
- 1998-04-17 AT AT98924161T patent/ATE366250T1/de not_active IP Right Cessation
- 1998-04-17 WO PCT/EP1998/002357 patent/WO1998049157A1/en not_active Ceased
- 1998-04-17 NZ NZ336233A patent/NZ336233A/xx unknown
- 1998-04-17 SK SK1461-99A patent/SK146199A3/sk unknown
- 1998-04-17 CN CN98804366A patent/CN1094937C/zh not_active Expired - Lifetime
- 1998-04-24 ZA ZA9803504A patent/ZA983504B/xx unknown
1999
- 1999-10-22 NO NO19995169A patent/NO317576B1/no unknown
2000
- 2000-10-13 US US09/687,153 patent/US6358961B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
TR199902606T2 (xx)	2000-07-21
ES2289783T3 (es)	2008-02-01
US6177432B1 (en)	2001-01-23
NO995169D0 (no)	1999-10-22
JP4308919B2 (ja)	2009-08-05
DE69838025D1 (de)	2007-08-16
NO317576B1 (no)	2004-11-15
PL336468A1 (en)	2000-06-19
JP2001522364A (ja)	2001-11-13
CA2288140A1 (en)	1998-11-05
EP0977750A1 (en)	2000-02-09
HUP0001122A3 (en)	2002-03-28
IL130363A0 (en)	2000-06-01
DE69838025T2 (de)	2008-05-08
CZ371799A3 (cs)	2000-02-16
CA2288140C (en)	2007-04-03
ATE366250T1 (de)	2007-07-15
RU2205831C2 (ru)	2003-06-10
HUP0001122A2 (hu)	2001-04-28
IL130363A (en)	2002-08-14
EP0977750B1 (en)	2007-07-04
NO995169L (no)	1999-12-27
CN1094937C (zh)	2002-11-27
PL190944B1 (pl)	2006-02-28
CN1252800A (zh)	2000-05-10
BR9809398A (pt)	2000-06-13
NZ336233A (en)	2001-01-26
AU7646098A (en)	1998-11-24
KR20000069560A (ko)	2000-11-25
CZ296959B6 (cs)	2006-08-16
US6358961B1 (en)	2002-03-19
WO1998049157A1 (en)	1998-11-05
ZA983504B (en)	1999-10-25
KR100520401B1 (ko)	2005-10-12
AU738628B2 (en)	2001-09-20

Publication	Publication Date	Title
SK146199A3 (en)	2000-06-12	Farnesyltransferase inhibiting quinazolinones
US6444812B1 (en)	2002-09-03	Intermediate compounds in the preparation of farnnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N-or C linked imidazoles
EP1322650B1 (en)	2008-09-24	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1140935B1 (en)	2003-05-14	1,2-annelated quinoline derivatives
EP1110953B1 (en)	2009-10-28	Quinazoline derivatives
SK162001A3 (en)	2002-04-04	Pharmaceutical compositions comprising 2-quinolones
AU2009228945B2 (en)	2013-05-02	Quinazolinone derivatives as tubulin polymerization inhibitors
MXPA99009763A (en)	2000-09-04	Farnesyltransferase inhibiting quinazolinones
HK1024689B (en)	2004-03-05	Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
HK1038740B (en)	2010-02-05	Quinazoline derivatives
CZ316799A3 (cs)	2000-03-15	1,8-Anelované chinolinonové deriváty substituované N- nebo C-vázanými imidazoly inhibující farnesyl transferázu